A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study

被引：0
|
作者：
Gao, Xin
Smith, Matthew Raymond
Scher, Howard I.
Verholen, Frank
Adorjan, Patrick
Dissanayake, Manjari
Laccetti, Andrew Leonard
机构：
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Bayer Consumer Care AG, Basel, Switzerland
[5] Bayer Healthcare Pharmaceut Inc, Whippany, NJ 07981 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5111
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis
    Kilari, D.
    Zittel, J.
    Patel, A.
    Sahasrabudhe, D.
    Feng, C.
    Burfeind, J.
    Guancial, E.
    Messing, E.
    Bylow, K.
    Mohile, S.
    Fung, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S540 - S541
  • [42] ODENZA, a Prospective, Randomized, Open-Label, Multicenter, Cross-Over Phase 2 Trial of Preference Between Darolutamide and Enzalutamide in Men With Asymptomatic or Mildly Symptomatic Metastatic Castrate-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 16 - 17
  • [43] DEGARELIX VERSUS LEUPROLIDE DEPOT (7.5 MG): RESULTS FROM A 12-MONTH, RANDOMIZED, OPEN-LABEL, PHASE III STUDY IN PATIENTS WITH PROSTATE CANCER
    Persson, B. E.
    Boccon-Gibod, L.
    Klotz, L.
    Schroder, F. H.
    Andreou, C.
    Cantor, P.
    Jensen, J. K.
    Olesen, T. K.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S318 - S318
  • [44] A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
    Agarwal, Neeraj
    Azad, Arun
    Carles, Joan
    Chowdhury, Simon
    McGregor, Bradley
    Merseburger, Axel S.
    Oudard, Stephane
    Saad, Fred
    Soares, Andrey
    Benzaghou, Fawzi
    Kerloeguen, Yannick
    Kimura, Akiko
    Mohamed, Nehal
    Panneerselvam, Ashok
    Wang, Fong
    Pal, Sumanta
    FUTURE ONCOLOGY, 2022, 18 (10) : 1185 - 1198
  • [45] An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
    Schmidt, M.
    Scheulen, M. E.
    Dittrich, C.
    Obrist, P.
    Marschner, N.
    Dirix, L.
    Schmidt, M.
    Ruettinger, D.
    Schuler, M.
    Reinhardt, C.
    Awada, A.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 275 - 282
  • [46] Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
    Teply, Benjamin A.
    Wang, Hao
    Luber, Brandon
    Sullivan, Rana
    Rifkind, Irina
    Bruns, Ashley
    Spitz, Avery
    DeCarli, Morgan
    Sinibaldi, Victoria
    Pratz, Caroline F.
    Lu, Changxue
    Silberstein, John L.
    Luo, Jun
    Schweizer, Michael T.
    Drake, Charles G.
    Carducci, Michael A.
    Paller, Channing J.
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    LANCET ONCOLOGY, 2018, 19 (01): : 76 - 86
  • [47] A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA
    Colomba, Emeline
    Jonas, Sarah Flora
    Eymard, Jean-Christophe
    Delva, Remi
    Brachet, Pierre Emmanuel
    Neuzillet, Yann
    Penel, Nicolas
    Roubaud, Guilhem
    Bompas, Emmanuelle
    Mahammedi, Hakim
    Longo, Raffaelle
    Helissey, Carole
    Barthelemy, Philippe
    Borchiellini, Delphine
    Hasbini, Ali
    Priou, Franck
    Saldana, Carolina
    Voog, Eric
    Narcisso, Berangere
    Ladoire, Sylvain
    Berdah, Jean-Francois
    Aisenfarb, Jean-Baptiste
    Foulon, Stephanie
    Fizazi, Karim
    EUROPEAN UROLOGY, 2024, 85 (03) : 274 - 282
  • [48] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    Cortes, Javier
    O'Shaughnessy, Joyce
    Loesch, David
    Blum, Joanne L.
    Vahdat, Linda T.
    Petrakova, Katarina
    Chollet, Philippe
    Manikas, Alexey
    Dieras, Veronique
    Delozier, Thierry
    Vladimirov, Vladimir
    Cardoso, Fatima
    Koh, Han
    Bougnoux, Philippe
    Dutcus, Corina E.
    Seegobin, Seth
    Mir, Denis
    Meneses, Nicole
    Wanders, Jantien
    Twelves, Chris
    LANCET, 2011, 377 (9769): : 914 - 923
  • [49] Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study
    Pedley, I. D.
    Frew, J. A.
    Wilson, J. M.
    Razak, A. R. Abdul
    Azzabi, A.
    McMenemin, R.
    Stockley, J.
    Soomro, N.
    Durkan, G.
    Leung, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [50] An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer
    MacVicar, G.
    Greco, F. A.
    Reeves, J.
    Curti, B.
    Poiesz, B.
    Somer, B.
    Brill, K.
    Leopold, L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 66 - 66
12345